Conditions:  Platinum-resistant Ovarian Cancer;  Fallopian Tube Cancer;  Primary Peritoneal Cancer
Interventions:  Biological: Nemvaleukin and Pembrolizumab Combination;  Biological: Pembrolizumab;  Biological: Nemvaleukin;  Drug: Pegylated Liposomal Doxorubicin (PLD);  Drug: Paclitaxel;  Drug: Topotecan;  Drug: Gemcitabine
Sponsors:  Alkermes, Inc.;  Merck Sharp & Dohme LLC
**RECRUITING NOW**
Interventions:  Biological: Nemvaleukin and Pembrolizumab Combination;  Biological: Pembrolizumab;  Biological: Nemvaleukin;  Drug: Pegylated Liposomal Doxorubicin (PLD);  Drug: Paclitaxel;  Drug: Topotecan;  Drug: Gemcitabine
Sponsors:  Alkermes, Inc.;  Merck Sharp & Dohme LLC
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
